Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study

BACKGROUND: Trastuzumab and fulvestrant combination therapy is one of the treatment options for patients with hormone receptor- and human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer; however, there are limited studies evaluating the efficacy of this combination therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Ozaki, Yukinori, Aoyama, Yosuke, Masuda, Jun, Inagaki, Lina, Kawai, Saori, Shibayama, Tomoko, Maeda, Tetsuyo, Kurata, Mami, Yoshida, Kazuyo, Saeki, Sumito, Hosonaga, Mari, Fukada, Ippei, Hara, Fumikata, Kobayashi, Takayuki, Kobayashi, Kokoro, Miyake, Satoshi, Takano, Toshimi, Ueno, Takayuki, Ohno, Shinji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728947/
https://www.ncbi.nlm.nih.gov/pubmed/34983437
http://dx.doi.org/10.1186/s12885-021-09128-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728947/
https://www.ncbi.nlm.nih.gov/pubmed/34983437
http://dx.doi.org/10.1186/s12885-021-09128-1

Ejemplares similares